Items where Author is "Rettig, MP"

Journal article

VADAKEKOLATHU, J., LAI, C., REEDER, S., CHURCH, S.E., HOOD, T., LOURDUSAMY, A., RETTIG, M.P., ALDOSS, I., ADVANI, A.S., GODWIN, J., WIEDUWILT, M.J., ARELLANO, M., MUTH, J., YAU, T.O., RAVANDI, F., SWEET, K., ALTMANN, H., FOULDS, G.A., STÖLZEL, F., MIDDEKE, J.M., CICIARELLO, M., CURTI, A., VALK, P.J.M., LÖWENBERG, B., GOJO, I., BORNHÄUSER, M., DIPERSIO, J.F., DAVIDSON-MONCADA, J.K. and RUTELLA, S., 2020. TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. Blood Advances, 4 (20), pp. 5011-5024. ISSN 2473-9529

UY, G.L., ALDOSS, I., FOSTER, M.C., SAYRE, P.H., WIEDUWILT, M.J., ADVANI, A.S., GODWIN, J.E., ARELLANO, M.L., SWEET, K., EMADI, A., RAVANDI, F., ERBA, H.P., BYRNE, M., MICHAELIS, L.C., TOPP, M.S., VEY, N., CICERI, F., CARRABBA, M.G., PAOLINI, S., HULS, G., JONGEN-LAVRENCIC, M., WERMKE, M., CHEVALLIER, P., GYAN, E., RÉCHER, C., STIFF, P., PETTIT, K., LÖWENBERG, B., CHURCH, S., ANDERSON, E.K., VADAKEKOLATHU, J., SANTAGUIDA, M.T., RETTIG, M.P., MUTH, J., CURTIS, T., FEHR, E., GUO, K., ZHAO, J., BAKKACHA, O., JACOBS, K., TRAN, K., KAMINKER, P., KOSTOVA, M., BONVINI, E., WALTER, R.B., DAVIDSON-MONCADA, J.K., RUTELLA, S. and DIPERSIO, J.F., 2020. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. ISSN 0006-4971

VADAKEKOLATHU NARAYANAN, J., MINDEN, M.D., HOOD, T., CHURCH, S.E., REEDER, S., ALTMANN, H., SULLIVAN, A.H., VIBOCH, E.J., PATEL, T., IBRAHIMOVA, N., WARREN, S.E., ARRUDA, A., LIANG, Y., SMITH, T.H., FOULDS, G.A., BAILEY, M.D., GOWEN-MACDONALD, J., MUTH, J., SCHMITZ, M., POCKLEY, A.G., CESANO, A., VALK, P.J.M., LÖWENBERG, B., BORNHÄUSER, M., TASIAN, S.K., RETTIG, M.P., DAVIDSON-MONCADA, J., DIPERSIO, J.F. and RUTELLA, S., 2020. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Science Translational Medicine, 12 (546): eaaz0463. ISSN 1946-6234

UY, G.L., RETTIG, M.P., VEY, N., GODWIN, J., FOSTER, M.C., RIZZIERI, D.A., ARELLANO, M.L., TOPP, M.S., HULS, G., JONGEN-LAVRENCIC, M., MARTINELLI, G., PAOLINI, S., CICERI, F., CARRABBA, M.G., SWEET, K.L., RAVANDI, F., CHURCH, S.E., VADAKEKOLATHU, J., RUTELLA, S., SUN, J., YANG, K., BAUGHMAN, J., CURTIS, T., TIMMENY, E., CALI, K., TRAN, K., MUTH, J., LA MOTTE-MOHS, R., POIROT, C., PALLIS, A., CESANO, A., BONVINI, E., WIGGINGTON, J., LOWENBERG, B., DAVIDSON-MONCADA, J.K. and DIPERSIO, J.F., 2018. Phase 1 cohort expansion of flotetuzumab, a CD123×CD3 bispecific Dart® protein in patients with relapsed/refractory acute myeloid leukemia (AML). Blood, 132 (S1): 764. ISSN 0006-4971